Business Wire

Kartrider: Drift’s Preseason Brings Arcade Thrills to Kart Racing Fans on PC and Mobile Platforms

12.1.2023 07:16:00 EET | Business Wire | Press release

Share

Starting today, KartRider: Drift , Nexon’s highly anticipated free-to-play kart racing party game, is available to download and play on PC and mobile platforms via Steam, Nexon Launcher, iOS App Store, and Google Play.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111006031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

KartRider: Drift from Nexon America now available on Steam, iOS, and Android (Graphic: Business Wire)

During Preseason, racers can test their mettle on bright, colorful tracks against PC and mobile racers from around the globe, rendered in stunning Unreal® Engine 4 graphics.

With unique characters and karts, racers have complete control over customization options to express themselves fully and cross the finish line in style! More characters, karts, accessories, and emotes can be unlocked via the Racing Pass, where racers can complete different daily challenges and event challenges. Premium challenges are also available with the purchase of a Premium Racing Pass.

Racers are trained and challenged through a unique License System in a series of meticulously designed courses. In Time Attack Mode, racers can then test their skills to top the leaderboards.

KartRider: Drift brings the deep kart customization that PC and mobile players expect, while delivering arcade-quality racing thrills to casual and seasoned players alike. Now’s the time for players to put the pedal to the metal – download KartRider: Drift and burn rubber!

NOTE FOR EDITORS:
KartRider: Drift’s Preseason launch on January 11 is only for PC (Steam, Nexon Launcher) and mobile (iOS, Android) players.

Playstation and Xbox console players will be able to join PC and mobile racers beginning with Season 1 (S1 launch to be announced at a later date).

Nexon’s KartRider Rush+ mobile racing game, launched in 2020, will continue to operate as a standalone title and does not share cross-play with KartRider: Drift.

Assets: Image | Trailer

Social Media: Twitch / Twitter / Instagram / Discord / Facebook / YouTube

About Kartrider: Drift
KartRider: Drift is Nexon’s new multiplayer kart racing party game, taking inspiration from earlier titles in the KartRider franchise, delivering drift-fueled racing action and featuring multiple game modes and deep kart and character customization in stunning Unreal® Engine 4 graphics. Available on Steam, the Nexon Launcher, mobile (iOS and Android) during Preseason, and with Xbox and PlayStation consoles joining at the launch of Season 1, KartRider: Drift offers free-to-play, online cross-platform play and progression to challenge friends regardless of the platform they choose.

Launched in 2004, the original KartRider was the first title in Nexon’s legendary kart racing series, and subsequently gained huge popularity in Asia and beyond, amassing more than 380 million players during the nineteen years since release. As a franchise, KartRider has established a strong brand across Asian markets and a huge eSports presence in Asia, with an official league starting in 2005. It continues to be the longest-running eSports league to date.

About Nexon America Inc.
Founded in 2006, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

North America and LATAM
Brian Klotz, Nexon America
NA_pr@nexon.com

Europe and UK
Heaven Media
nexon@heavenmedia.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 10:00:00 EEST | Press release

ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to operational execution, but organisations cannot scale AI without trust, visibility, and control,” sai

Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release

Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin

BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release

BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels

Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye